Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …

This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …

Key physiological functions of the liver, including glucose and lipid metabolism, become
disturbed in the setting of non-alcoholic fatty liver disease (NAFLD) and may be associated …

Background & Aims There have been many studies of the effects of non-alcoholic fatty liver
disease (NAFLD) and the risk of cardiovascular disease (CVD), but these have produced …

Hepatic steatosis is an underlying feature of nonalcoholic fatty liver disease (NAFLD), which
is the most common form of liver disease and is present in up to∼ 70% of individuals who …

The Clinical Practice Guidelines (CPG) propose recommendations for the diagnosis,
treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
in Western countries that is predicted to become also the most frequent indication for liver …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis,
nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease
in the world, paralleling the epidemic of obesity and Type 2 diabetes mellitus (T2DM) …

Nonalcoholic fatty liver disease (NAFLD) is a multisystemic clinical condition that presents
with a wide spectrum of extrahepatic manifestations, such as obesity, type 2 diabetes …